SemaglutideRecent, repeatedEvidence- NCT07866066 · Amgen · Phase 3 · live · comparator · “Semaglutide” · registered Oct 2026
- NCT07801820 · Lepu Medical · Phase 2 · live · comparator · “Semaglutide Tablets” · registered Aug 2026
- NCT07743983 · BrightGene Bio-Medical Technology Co., Ltd. · Phase 3 · live · comparator · “semaglutide” · registered Jul 2026
- NCT07662213 · AstraZeneca · Phase 3 · live · comparator · “Semaglutide” · registered Jun 2026
- NCT07653477 · The United Laboratories International Holdings Limited · Phase 3 · live · comparator · “Semaglutide Injection” · registered Jun 2026
| Novo Nordisk A/S89% of its industry studiesUS: Novo Nordisk A/S (FDA 2019)EU: Novo Nordisk A/S (EMA 2018) | 1521 studies | 1113 studies | comparator 23 · background 1 |
MetforminRecent, repeatedPhase 4 trial recordedEvidence- NCT07442006 · JW Pharmaceutical · Phase 4 · live · comparator · “Metformin” · registered Jan 2026
- NCT07244003 · Huadong Medicine Co., Ltd. · Phase 4 · live · background · “Metformin” · registered Nov 2025
- NCT07093476 · Celltrion · Phase 3 · live · background · “Metformin” · registered Jun 2025
- NCT06972732 · Boryung Pharmaceutical Co., Ltd · Phase 4 · live · background · “Metformin” · registered May 2025
- NCT06339086 · chengdu brilliant pharmaceutical co ltd · Phase 3 · live · background · “Metformin” · registered Mar 2024
| AstraZeneca9% of its industry studies | 1212 studies | 77 studies | background 211 · comparator 48 |
dapagliflozinRecent, repeatedEvidence- NCT07082114 · Huadong Medicine Co., Ltd. · Phase 3 · live · comparator · “Dapagliflozin (DAPA)” · registered Jul 2025
- NCT06972732 · Boryung Pharmaceutical Co., Ltd · Phase 4 · live · comparator · “Dapagliflozin/Sitagliptin” · registered May 2025
- NCT06589765 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · comparator · “dapagliflozin tablet” · registered Sep 2024
- NCT06415773 · Shenzhen HighTide Biopharmaceutical Ltd. · Phase 3 · comparator · “Dapagliflozin” · registered May 2024
- NCT06192108 · Eli Lilly and Company · Phase 3 · comparator · “Dapagliflozin” · registered Dec 2023
| AstraZeneca82% of its industry studiesUS: off-patent, 22 generics marketedEU: off-patent, 1 generic authorized | 88 studies | 44 studies | comparator 11 · background 4 |
dulaglutideRecent, repeatedEvidence- NCT07156539 · Hansoh Pharmaceutical Group Company Limited · Phase 3 · live · comparator · “Dulaglutide Injection” · registered Aug 2025
- NCT07109700 · Huadong Medicine Co., Ltd. · Phase 2 · live · comparator · “Dulaglutide 1.5 MG” · registered Jul 2025
- NCT06901648 · Hansoh Pharmaceutical Group Company Limited · Phase 2 · comparator · “Dulaglutide” · registered Feb 2025
- NCT06257966 · Beijing Dongfang Biotech Co., Ltd. · Phase 3 · live · comparator · “Dulaglutide” · registered Feb 2024
- NCT05680129 · Hangzhou Sciwind Biosciences Co., Ltd. · Phase 3 · comparator · “Dulaglutide” · registered Dec 2022
| Eli Lilly and Company96% of its industry studiesUS: Eli Lilly and Company (FDA 2014)EU: Eli Lilly and Company (EMA 2014) | 56 studies | 33 studies | comparator 11 · background 1 |
insulin degludecRecent, repeatedEvidence- NCT07913061 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “insulin degludec” · registered Oct 2026
- NCT07527078 · Gan & Lee Pharmaceuticals · Phase 3 · live · comparator · “Insulin Degludec Injection (Tresiba®)” · registered Apr 2026
- NCT07215312 · Eli Lilly and Company · Phase 2 · live · comparator · “Degludec” · registered Oct 2025
- NCT07018453 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · comparator · “Insulin Degludec” · registered Jun 2025
- NCT06202079 · Gan & Lee Pharmaceuticals · Phase 2 · comparator · “Insulin Degludec” · registered Jan 2024
| Novo Nordisk A/S93% of its industry studiesUS: Novo Nordisk A/S (FDA 2015)EU: Novo Nordisk A/S (EMA 2013) | 49 studies | 45 studies | comparator 17 · background 2 |
TirzepatideRecent, repeatedEvidence- NCT07889648 · Hoffmann-La Roche · Phase 3 · live · comparator · “Tirzepatide” · registered Oct 2026
- NCT07796477 · CSPC Pharmaceutical Group Limited · Phase 2 · live · comparator · “Tirzepatide Injection 15mg” · registered Aug 2026
- NCT06534411 · Novo Nordisk A/S · Phase 3 · comparator · “Tirzepatide” · registered Jul 2024
- NCT06221969 · Novo Nordisk A/S · Phase 3 · comparator · “Tirzepatide” · registered Jan 2024
| Eli Lilly and Company96% of its industry studiesUS: Eli Lilly and Company (FDA 2022)EU: Eli Lilly and Company (EMA 2022) | 34 studies | 22 studies | comparator 4 |
Insulin GlargineRecent, repeatedEvidence- NCT06871761 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · comparator · “insulin glargine” · registered Feb 2025
- NCT06688123 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · comparator · “Insulin glargine” · registered Nov 2024
- NCT06370715 · Eli Lilly and Company · Phase 4 · background · “Insulin Glargine” · registered Apr 2024
- NCT06269107 · Novo Nordisk A/S · Phase 3 · comparator · “Insulin glargine” · registered Feb 2024
- NCT05803421 · Eli Lilly and Company · Phase 3 · comparator · “Insulin Glargine” · registered Mar 2023
| Sanofi65% of its industry studiesUS: Sanofi (FDA 2000) + 3 othersEU: Sanofi (EMA 2000) + 3 others | 38 studies | 00 studies | background 21 · comparator 77 |
mazdutideRecent, repeatedEvidence- NCT07843862 · Jiangsu HengRui Medicine Co., Ltd. · Phase 2 · live · comparator · “Mazdutide” · registered Sep 2026
- NCT07417306 · Huadong Medicine Co., Ltd. · Phase 3 · live · comparator · “Mazdutide” · registered Feb 2026
| Innovent Biologics, Inc.74% of its industry studies | 22 studies | 22 studies | comparator 2 |
Insulin AspartRecent, repeatedEvidence- NCT06558708 · Gan & Lee Pharmaceuticals · Phase 2 · live · background · “Insulin aspart” · registered Aug 2024
- NCT05413369 · Sanofi · Phase 3 · comparator · “IDegAsp” · registered Jun 2022
- NCT04974528 · Mannkind Corporation · Phase 3 · comparator · “Rapid-acting Insulin Analog” · registered Jun 2021
- NCT03430856 · Biocon Limited · Phase 3 · comparator · “Insulin Aspart” · registered Nov 2017
- NCT03211858 · Sanofi · Phase 3 · comparator · “NovoLog/NovoRapid” · registered Jul 2017
| Novo Nordisk A/S88% of its industry studiesUS: Novo Nordisk A/S (FDA 2001) + 1 otherEU: Novo Nordisk A/S (EMA 1999) + 3 others | 22 studies | 11 study | comparator 11 · background 3 |
empagliflozinRecent, repeatedEvidence- NCT06083675 · Novo Nordisk A/S · Phase 3 · comparator · “Empagliflozin” · registered Oct 2023
- NCT05444153 · Novo Nordisk A/S · Phase 3 · comparator · “Empagliflozin” · registered Jun 2022
- NCT05232071 · Inventiva Pharma · Phase 2 · background · “Empagliflozin” · registered Jan 2022
- NCT05028140 · EMS · Phase 3 · live · comparator · “EMPAGLIFLOZIN” · registered Aug 2021
- NCT04970108 · EMS · Phase 3 · comparator · “Empagliflozin + telmisartan” · registered Jul 2021
| Boehringer Ingelheim70% of its industry studiesEU: Boehringer Ingelheim (EMA 2014) | 23 studies | 14 studies | background 2 · comparator 10 |
alogliptinRecent, repeatedEvidence- NCT07093476 · Celltrion · Phase 3 · live · background · “Alogliptin” · registered Jun 2025
- NCT05782192 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 3 · comparator · “Alogliptin” · registered Mar 2023
- NCT03499704 · Celltrion · Phase 4 · comparator · “Alogliptin” · registered Apr 2018
| Takeda92% of its industry studiesUS: Takeda (FDA 2013)EU: Takeda (EMA 2013) | 22 studies | 11 study | comparator 2 · background 1 |